As shown previously, drug targets with support from monogenic and population genetic studies are more likely to proceed successfully through the drug development pipeline and be approved.(88, 89) It is possible that targeting GALNT3‐dependent BMD pathways may open a new avenue in the search for new anabolic treatments for osteoporosis. Here, GALNT3 is linked to osteoporosis.